Selective Factor Xa Inhibition Improves Efficacy of Venous Thromboembolism Prophylaxis in Orthopedic Surgery

@article{Comp2003SelectiveFX,
  title={Selective Factor Xa Inhibition Improves Efficacy of Venous Thromboembolism Prophylaxis in Orthopedic Surgery},
  author={P C Comp},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2003},
  volume={23}
}
  • P. Comp
  • Published 1 June 2003
  • Medicine, Biology
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Venous thromboembolism is a serious, frequent, and potentially fatal complication of major orthopedic surgery. Currently available pharmacologic agents for the prevention of venous thromboembolism in this high‐risk population consist of the oral anticoagulants and the heparin family of antithrombotic agents (unfractionated heparin, low‐molecular‐weight heparin, heparinoids). These classes of agents interfere with the activity of both thrombin and factor Xa (or their respective zymogens) to… 
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
TLDR
Apixaban is an orally bioavailable inhibitor of factor Xa with elimination pathways that include metabolism and renal excretion with no serious adverse events or discontinuations due to adverse effects.
Venous thromboprophylaxis : reducing needlestick injury
TLDR
The emotional effect on the person injured may be significant, regardless of the potential transmission of infection, and may evoke or intensify feelings of fear linked with future needle use (Lee et al 2005).
Comparative Metabolism of 14 C-Labeled Apixaban in Mice , Rats , Rabbits , Dogs , and Humans
TLDR
Overall, apixaban was effectively eliminated via multiple elimination pathways in animals and humans, including oxidative metabolism, and direct renal and in-situ excretion of the drug from gastrointestinal tracts of rats.
Comparative Metabolism of 14C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans
TLDR
Overall, apixaban was effectively eliminated via multiple elimination pathways in animals and humans, including oxidative metabolism, and direct renal and intestinal excretion.

References

SHOWING 1-10 OF 157 REFERENCES
Deep-vein thrombosis prophylaxis in orthopedic surgery: hip surgery.
Hip replacement surgery carries a high risk of thromboembolic complications, and pharmacological prophylaxis is routinely adopted in clinical practice. Meta-analyses have indicated that low molecular
Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty
TLDR
This randomized, controlled trial compared ximelagatran with warfarin in 680 patients undergoing total knee arthroplasty and found that xIMelag atran was at least as effective as warfar in the prevention of venous thromboembolism.
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
TLDR
In patients undergoing orthopedic surgery, 2.5 mg of fondaparinux sodium once daily, starting 6 hours postoperatively, showed a major benefit over enoxaparin, achieving an overall risk reduction of VTE greater than 50% without increasing the risk of clinically relevant bleeding.
Efficacy and Safety of Enoxaparin to Prevent Deep Venous Thrombosis after Hip Replacement Surgery
TLDR
This dose-ranging study was done to compare the efficacy and safety of three postoperative enoxaparin dose regimens to prevent deep venous thrombosis in patients having total hip replacement surgery and identified a clinically effective dose with a minimal risk for hemorrhagic complications.
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
TLDR
Fixed-dose, unmonitored ximelagatran, 24 mg twice daily, given after surgery appears to be safe and effective oral prophylaxis against venous thromboembolism after total knee replacement.
First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation
TLDR
This is the first study of a selective, reversible, and direct small-molecule factor Xa inhibitor in patients with stable coronary disease and lays the foundation for further investigation of factor XA inhibitors in the treatment of patients with coronary atherothrombosis.
A COMPARISON OF RECOMBINANT HIRUDIN WITH A LOW-MOLECULAR-WEIGHT HEPARIN TO PREVENT THROMBOEMBOLIC COMPLICATIONS AFTER TOTAL HIP REPLACEMENT
TLDR
When administered 30 minutes before total hip replacement, desirudin is more effective than enoxaparin in preventing deep-vein thrombosis, and the safety profiles were similar in the two treatment groups.
Comparison of two low‐molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery
TLDR
The two treatment groups were clinically equivalent in efficacy, and the reviparin-treated patients had fewer haematomas, bruisings and higher red cell counts and lower haemoglobin levels than the enoxaparin- treated patients.
Use of selective factor Xa inhibitors in special populations.
  • A. Turpie
  • Medicine
    American journal of orthopedics
  • 2002
TLDR
Fondaparinux is a selective factor Xa inhibitor that can be administered safely and efficaciously in a wide variety of patient populations, without the need for dosage modification.
...
1
2
3
4
5
...